Sara J Knight1,2, Ateesha F Mohamed3, Deborah A Marshall4, Uri Ladabaum5, Kathryn A Phillips6, Judith M E Walsh7. 1. Health Services Research and Development Program, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, USA (SJK) 2. Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA (SJK) 3. CHEOR, Specialty Medicine, Bayer Healthcare Pharmaceuticals, Inc., Whippany, New Jersey, USA (AFM) 4. Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada (DAM) 5. Department of Medicine, Stanford University, Palo Alto, California, USA (UL) 6. Department of Clinical Pharmacy and Institute for Health Policy Studies, University of California at San Francisco, San Francisco, California, USA (KAP) 7. Departments of Medicine and Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, California, USA (JMEW)
Abstract
BACKGROUND: . While choices about genetic testing are increasingly common for patients and families, and public opinion surveys suggest public interest in genomics, it is not known how adults from the general population value genetic testing for heritable conditions. We sought to understand in a US sample the relative value of the characteristics of genetic tests to identify risk of hereditary colorectal cancer, among the first genomic applications with evidence to support its translation to clinical settings. METHODS: . A Web-enabled choice-format conjoint survey was conducted with adults age 50 years and older from a probability-based US panel. Participants were asked to make a series of choices between 2 hypothetical blood tests that differed in risk of false-negative test, privacy, and cost. Random parameters logit models were used to estimate preferences, the dollar value of genetic information, and intent to have genetic testing. RESULTS: . A total of 355 individuals completed choice-format questions. Cost and privacy were more highly valued than reducing the chance of a false-negative result. Most (97% [95% confidence interval (CI)], 95%-99%) would have genetic testing to reduce the risk of dying of colorectal cancer in the best scenario (no false negatives, results disclosed to primary care physician). Only 41% (95% CI, 25%-57%) would have genetic testing in the worst case (20% false negatives, results disclosed to insurance company). CONCLUSIONS: . Given the characteristics and levels included in the choice, if false-negative test results are unlikely and results are shared with a primary care physician, the majority would have genetic testing. As genomic services become widely available, primary care professionals will need to be increasingly knowledgeable about genetic testing decisions.
BACKGROUND: . While choices about genetic testing are increasingly common for patients and families, and public opinion surveys suggest public interest in genomics, it is not known how adults from the general population value genetic testing for heritable conditions. We sought to understand in a US sample the relative value of the characteristics of genetic tests to identify risk of hereditary colorectal cancer, among the first genomic applications with evidence to support its translation to clinical settings. METHODS: . A Web-enabled choice-format conjoint survey was conducted with adults age 50 years and older from a probability-based US panel. Participants were asked to make a series of choices between 2 hypothetical blood tests that differed in risk of false-negative test, privacy, and cost. Random parameters logit models were used to estimate preferences, the dollar value of genetic information, and intent to have genetic testing. RESULTS: . A total of 355 individuals completed choice-format questions. Cost and privacy were more highly valued than reducing the chance of a false-negative result. Most (97% [95% confidence interval (CI)], 95%-99%) would have genetic testing to reduce the risk of dying of colorectal cancer in the best scenario (no false negatives, results disclosed to primary care physician). Only 41% (95% CI, 25%-57%) would have genetic testing in the worst case (20% false negatives, results disclosed to insurance company). CONCLUSIONS: . Given the characteristics and levels included in the choice, if false-negative test results are unlikely and results are shared with a primary care physician, the majority would have genetic testing. As genomic services become widely available, primary care professionals will need to be increasingly knowledgeable about genetic testing decisions.
Authors: Bernard Levin; James S Barthel; Randall W Burt; Donald S David; James M Ford; Francis M Giardiello; Stephen B Gruber; Amy L Halverson; Stanley Hamilton; Wendy Kohlmann; Kirk A Ludwig; Patrick M Lynch; Christopher Marino; Edward W Martin; Robert J Mayer; Boris Pasche; Samuel J Pirruccello; Ashwani Rajput; M Sambasiva Rao; Moshe Shike; Gideon Steinbach; Jonathan P Terdiman; David Weinberg; Sidney J Winawer Journal: J Natl Compr Canc Netw Date: 2006-04 Impact factor: 11.908
Authors: Donald W Hadley; Jean Jenkins; Eileen Dimond; Kenneth Nakahara; Liam Grogan; David J Liewehr; Seth M Steinberg; Ilan Kirsch Journal: Arch Intern Med Date: 2003-03-10
Authors: F Reed Johnson; Emily Lancsar; Deborah Marshall; Vikram Kilambi; Axel Mühlbacher; Dean A Regier; Brian W Bresnahan; Barbara Kanninen; John F P Bridges Journal: Value Health Date: 2013 Jan-Feb Impact factor: 5.725
Authors: Sarah T Hawley; Robert J Volk; Partha Krishnamurthy; Maria Jibaja-Weiss; Sally W Vernon; Suzanne Kneuper Journal: Med Care Date: 2008-09 Impact factor: 2.983
Authors: Sharon L Manne; Daniel C Chung; David S Weinberg; Hetal S Vig; Zohra Catts; Melissa Klein Cabral; Kristen Shannon; Neal J Meropol Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-10 Impact factor: 4.254
Authors: Andreas Andersson; Carolina Hawranek; Anna Öfverholm; Hans Ehrencrona; Kalle Grill; Senada Hajdarevic; Beatrice Melin; Emma Tham; Barbro Numan Hellquist; Anna Rosén Journal: Hered Cancer Clin Pract Date: 2020-09-15 Impact factor: 2.857